You are a meticulous expert reviewer comparing four answers to the SAME research
question, each generated from a different (undisclosed) evidence-retrieval method over
the same personal paper library. Judge ONLY answer quality. Do not try to guess the method.

Score each answer 1-10 on each dimension:
- coverage: how many of the genuinely relevant papers/points are represented.
- synthesis: quality of CROSS-PAPER structure (consensus, disagreement, lineage/subsumption,
  taxonomy) -- NOT just a list of per-paper summaries.
- correctness: are the relational and technical claims ACCURATE? Heavily penalize hallucinated
  or wrong subsumption/contradiction claims (e.g. "X generalizes Y" when false).
- faithfulness: claims attributed to specific papers; no unsupported assertions; no outside facts.
- directness: answers the actual question precisely without padding (length is NOT a virtue).

Then give an overall ranking of the four (best to worst). Ties are NOT allowed in the ranking.

The relevant papers for this question (ground truth, for assessing coverage) are listed below.
Be skeptical: a confident, well-written answer can still be wrong or shallow.

Output STRICT JSON only, no prose:
{"scores": {"Option 1": {"coverage":N,"synthesis":N,"correctness":N,"faithfulness":N,"directness":N},
            "Option 2": {...}, "Option 3": {...}, "Option 4": {...}},
 "ranking": ["Option X","Option Y","Option Z","Option W"],
 "notes": "1-3 sentences on the key differentiators"}


=== QUESTION ===
Do my DNA language model papers agree they predict variant effects well -- and how does the benchmarking paper's conclusion compare to the method papers' own claims?

=== RELEVANT PAPERS (ground truth) ===
- Benchmarking DNA Sequence Models for Causal Regulatory Variant Prediction in Human Genetics (Benegas, Gonzalo; Eraslan, Gökcen; Song, Yun S.)
- A DNA language model based on multispecies alignment predicts the effects of genome-wide variants (Benegas, Gonzalo; Song, Yun S.; Albors, Carlos; Aw, Alan J.;)
- DNA language models are powerful predictors of genome-wide variant effects (Benegas, Gonzalo; Song, Yun S.; Batra, Sanjit Singh)
- Predicting expression-altering promoter mutations with deep learning (Jaganathan, Kishore; Ersaro, Nicole; Novakovsky, Gherman; Wa)

=== ANSWERS TO JUDGE ===
===== Option 1 =====
## Do the DNA language model papers agree they predict variant effects well, and how does the benchmark compare to the methods' own claims?

**The method papers make confident, largely self-consistent claims of strong performance — but those claims are scoped, and the benchmarking paper qualifies them substantially.**

### What the method papers claim about themselves

The two GPN-lineage method papers report strong results, but each carefully bounds its claim:

- *DNA language models are powerful predictors of genome-wide variant effects* (GPN) claims state-of-the-art VEP performance — but explicitly only **for *Arabidopsis thaliana***, a compact genome, and calls itself a "proof-of-concept model" that is 200x smaller than the largest protein LMs, with "room for improving its training scheme" [B6, B27, B35]. It frames the human genome as "substantially harder" and unsolved [B29].
- *A DNA language model based on multispecies alignment* (GPN-MSA) opens by conceding that "DNA language models have not yet shown a competitive edge for complex genomes such as that of humans," then claims GPN-MSA achieves "outstanding performance" on clinical, functional-assay, and population-genomic benchmarks (ClinVar, COSMIC, OMIM, DMS, DepMap, gnomAD) [B18, B19, B13, B26]. This is the strongest self-claim in the set.

So both method papers agree DNA LMs *can* predict variant effects well — but only GPN-MSA claims this for humans, and even it hedges in important ways (see below).

### Internal caveats already present in the method papers

The method papers are not uniformly triumphant. GPN-MSA itself cautions that "none of the models performs exceedingly well relative to ClinVar results," that sequence models like GPN-MSA are "less interpretable than functional genomics models such as SpliceAI and Enformer," and that jointly modeling sequence and functional genomics "may have the biggest impact" [B7, B5]. It also warns its scores are not "calibrated fitness estimates" and should only be used to compare variants relatively [B13]. These are meaningful concessions that DNA LMs are not a clear, universal winner.

### How the benchmarking paper compares

*Benchmarking DNA Sequence Models for Causal Regulatory Variant Prediction* (TraitGym) **partially corroborates and partially tempers** the method claims, and is more granular than any single-method paper:

- It confirms alignment-based models — **CADD and GPN-MSA — compare favorably for Mendelian traits and complex disease traits** [B25], consistent with GPN-MSA's self-claims.
- But it finds **functional-genomics-supervised models (Enformer, Borzoi) perform better for complex non-disease traits** [B25] — i.e., the self-supervised DNA LM advantage is trait-class dependent, not blanket. The benchmark explains this via mechanism: Mendelian variants are easier because they have larger effects and stronger purifying selection (the signal self-supervised models pick up), while complex traits differ [B8].
- It reports that **Evo2 shows gains with scale but still lags alignment-based models, struggling with enhancer variants** [B25], which complicates the method papers' implicit "scaling will keep improving DNA LMs" narrative [B6, B26].

The benchmark also implicitly critiques prior evaluation practice: it argues existing benchmarks (BEND, GV-Rep) lack adequate baselines — notably omitting conservation-based models that "are usually strong for this task" — and that ClinVar is skewed toward coding/splice variants with almost no intergenic/promoter variants [B23, B34]. This frames the method papers' headline numbers as needing stronger, conservation-aware baselines to be trusted.

### Bottom line

There is broad agreement that DNA LMs (especially alignment-based GPN-MSA) predict variant effects well **for Mendelian and disease variants**. The disagreement/tension is in scope: the original GPN claim was plant-only [B6]; GPN-MSA's "outstanding" human claim is real but trait-class- and baseline-dependent, and the benchmark shows DNA LMs are *not* uniformly best — functional-genomics models win for complex non-disease traits and conservation baselines remain strong [B25, B23]. Note three of these papers share Benegas/Song authorship [B10, B19, B25], so the "benchmark vs. method" comparison is partly self-critique rather than fully independent.

*(The promoter-mutation and protein-conformation entries [B11, B17, B21, B32] do not bear on DNA-LM variant-effect claims and are not used here.)*

===== Option 2 =====
## Do the DNA language model papers agree they predict variant effects well?

The relevant context comes from three method papers — GPN ("DNA language models are powerful predictors of genome-wide variant effects"), GPN-MSA ("A DNA language model based on multispecies alignment predicts the effects of genome-wide variants"), and PromoterAI ("Predicting expression-altering promoter mutations with deep learning") — plus one benchmarking paper, TraitGym ("Benchmarking DNA Sequence Models for Causal Regulatory Variant Prediction in Human Genetics"). They do not present a uniform "DNA LMs predict variant effects well" verdict; rather, the method papers claim strong but task-specific success, while the benchmark complicates that picture by showing where self-supervised DNA LMs lose.

### The method papers' own claims are positive but qualified

GPN claims to be the first DNA LM to demonstrate accurate *unsupervised* genome-wide variant effect prediction (defined via the log-likelihood ratio between alternate and reference allele at a masked position), achieving state-of-the-art performance in *Arabidopsis thaliana* — a notable scope limitation, since its headline result is in a plant, not human. GPN-MSA, the multispecies-alignment successor, makes the strongest human claims: on ClinVar pathogenic vs. gnomAD common missense classification it "substantially outperforms" other DNA LMs (Nucleotide Transformer, HyenaDNA) and also beats CADD, phyloP, and even the missense-specialist ESM-1b. Both papers explicitly frame themselves against *prior* DNA LMs that failed — GPN-MSA notes Nucleotide Transformer performed worse than simple conservation scores at unsupervised VEP even at large scale, motivating the MSA approach. So the method papers agree that *their* models predict variant effects well, while conceding earlier DNA LMs did not.

Crucially, the method papers self-report limitations: GPN-MSA "performs behind CADD on splice-region variants," and on deep mutational scanning across 31 human proteins the protein LM ESM-1b is best overall, with GPN-MSA only "comparable to CADD." PromoterAI, a fine-tuned (not purely self-supervised) model, reports strong promoter-variant classification (auROC 0.89/0.80/0.74) and beats Evo2, Enformer, Borzoi and others — but only in the narrow promoter-expression domain.

### How the benchmark's conclusion compares

TraitGym, which positions itself as the only benchmark covering both Mendelian and complex human non-coding traits and the only one evaluating supervised and self-supervised models against strong non-neural baselines, qualifies the method papers' optimism in two ways. First, it finds variant classification "substantially harder for complex traits than Mendelian traits," and attributes self-supervised models' success specifically to purifying-selection signal — which is strong for Mendelian variants but weaker for complex traits. Second, and most pointedly, it finds that "functional-genomics-supervised models Enformer and Borzoi perform better than alignment-based models for complex non-disease traits" — directly tempering the alignment-based GPN-MSA's strong-performance narrative on exactly the trait class where self-supervised LMs are weakest.

### Net assessment

There is broad agreement that DNA LMs *can* predict variant effects, but no agreement that they do so uniformly well. The method papers report wins on conservation-dominated tasks (ClinVar/Mendelian, missense) while themselves flagging splice and DMS weaknesses; the benchmark generalizes these into a structural conclusion — self-supervised/alignment-based DNA LMs excel where purifying selection is strong (Mendelian) but are outperformed by supervised functional-genomics models on complex traits. The context does not contain a head-to-head TraitGym ranking of GPN/GPN-MSA specifically, so the precise gap between the benchmark and each method paper's self-claims cannot be fully quantified from what is provided.

===== Option 3 =====
The method papers and the benchmarking paper do **not** fully agree: each method paper makes a strong, scoped "we predict variant effects well" claim, while the benchmark reframes those claims as conditional on trait type, variant category, and the strength of non-neural baselines.

**What the method papers claim.** The earliest GPN paper ("DNA language models are powerful predictors of genome-wide variant effects") claims state-of-the-art unsupervised variant effect prediction, but only demonstrates this in the compact genome of *Arabidopsis thaliana*, where GPN outperforms phyloP and phastCons. It does not claim success in humans; it explicitly notes that existing DNA language models "have not yet demonstrated the ability to make accurate variant effect predictions" on harder genomes. The follow-up, "A DNA language model based on multispecies alignment predicts the effects of genome-wide variants" (GPN-MSA), makes the human claim: by adding multispecies alignment, it reports "outstanding performance" across ClinVar, COSMIC, OMIM, DMS, DepMap and gnomAD, outperforming Nucleotide Transformer, HyenaDNA, CADD, phyloP, ESM-1b, Enformer and SpliceAI. Crucially, this paper is already candid about limits: on ClinVar missense with benign controls, GPN-MSA falls "marginally behind CADD and ESM-1b"; on deep mutational scanning, ESM-1b achieves the best overall performance; and it notes "none of the models performs exceedingly well relative to ClinVar results." PromoterAI ("Predicting expression-altering promoter mutations with deep learning") is a supervised, not self-supervised, model and a narrower case: it claims best-in-class performance on promoter expression-altering variants, beating Evo2, Enformer, Borzoi and others, but only within the promoter/expression-outlier task.

**How the benchmark compares.** "Benchmarking DNA Sequence Models for Causal Regulatory Variant Prediction in Human Genetics" (TraitGym) recasts the question on a curated, control-matched causal-variant task across 113 Mendelian and 83 complex traits. Its verdict is more qualified than a blanket "DNA LMs predict variant effects well":
- It finds that alignment-based models — CADD and GPN-MSA — "compare favorably for Mendelian traits and complex disease traits." This **supports** GPN-MSA's central human claim, but notably groups it with CADD rather than declaring it the clear winner, somewhat tempering GPN-MSA's reported margins over CADD.
- For complex non-disease traits, functional-genomics-supervised models (Enformer, Borzoi) do better, so no single class wins everywhere.
- Self-supervised, alignment-*free* DNA LMs fare worse: Evo2 "shows substantial performance gains with scale, but still lags somewhat behind alignment-based models, struggling particularly with enhancer variants." This is a direct **disagreement** with the implicit promise that scaling self-supervised DNA LMs alone yields strong variant prediction — echoing, in human data, the early GPN paper's own warning that alignment-free human DNA LMs (e.g., Nucleotide Transformer) underperformed conservation scores.
- The benchmark stresses that non-neural baselines (conservation scores, CADD) are strong and that prior self-supervised benchmarks (BEND, GV-Rep) lacked adequate baselines — an implicit critique that some method-paper claims looked stronger partly for want of rigorous controls.

**Bottom line.** The papers agree that *alignment-informed* DNA models predict variant effects well, especially for Mendelian and disease variants (consensus between GPN-MSA and TraitGym). They disagree on the strength of *alignment-free* self-supervised DNA LMs: method-paper rhetoric ("powerful predictors") is tempered by the benchmark, which shows these models lag conservation/alignment baselines and struggle on enhancers. The method papers' "we predict well" claims are largely upheld but narrowed in scope, and the benchmark adds the caveat that performance is strongly trait- and category-dependent.

(The context is sufficient for the human and Mendelian/complex comparisons; it does not contain TraitGym's specific numeric scores for GPN-MSA, so the precise size of agreement on margins cannot be quantified here.)

===== Option 4 =====
The method papers in this library are consistently optimistic about DNA language models (DNA LMs) for variant effect prediction (VEP), but the in-library benchmarking paper qualifies this picture substantially, showing that performance is real but conditional, model-dependent, and not uniformly dominant.

**The method papers' own claims (uniformly positive, but each with caveats).**

The original GPN paper ("DNA language models are powerful predictors of genome-wide variant effects") makes the strongest unqualified claim, asserting "state-of-the-art performance" and reporting that GPN "outperforms predictors based on popular conservation scores such as phyloP and phastCons." Crucially, however, this success is demonstrated in *Arabidopsis thaliana*, a compact model-organism genome, not the human genome.

The follow-up, "A DNA language model based on multispecies alignment predicts the effects of genome-wide variants," is notably candid that the human genome is the hard case. It states plainly that "DNA language models have not yet shown a competitive edge for complex genomes such as that of humans," and that earlier human DNA LMs (e.g., Nucleotide Transformer) showed "inferior performance compared to simpler conservation scores," even at large scale. Its positive claim is specifically about its new method, GPN-MSA, which adds multispecies alignment and reportedly achieves "outstanding performance on deleteriousness prediction for both coding and noncoding variants" across ClinVar, COSMIC, OMIM, DMS/DepMap, and gnomAD. So even within the method papers there is an implicit lineage and disagreement: plain DNA LMs do *not* work well on humans, and a step-change (adding alignments) was required.

**The benchmarking paper's conclusion (more measured, and partly subsumes the claims above).**

"Benchmarking DNA Sequence Models for Causal Regulatory Variant Prediction in Human Genetics" (the TraitGym paper) reframes the question on curated human non-coding causal variants and reaches a more nuanced verdict. It confirms the method papers' core message *only for the alignment-based variant*: "alignment-based models CADD and GPN-MSA compare favorably for Mendelian traits and complex disease traits." This is consistent with the GPN-MSA paper's self-assessment. However, it adds three qualifications the method papers do not foreground:
1. DNA LMs are not universally best — "functional-genomics-supervised models Enformer and Borzoi perform better for complex non-disease traits."
2. Scale alone is insufficient: Evo2 "shows substantial performance gains with scale, but still lags somewhat behind alignment-based models, struggling particularly with enhancer variants."
3. It stresses that the field "currently lacks consistently curated datasets with accurate labels, especially for non-coding variants," implicitly cautioning that the method papers' favorable benchmark results rest on heterogeneous, less-controlled evaluations.

**Net comparison.** There is broad agreement that DNA LMs *can* predict variant effects well, but the agreement is conditional, not blanket. The benchmarking paper does not contradict the method papers so much as bound them: it endorses GPN-MSA (alignment-based) for Mendelian and disease traits while showing that self-supervised DNA LMs lose to supervised functional-genomics models on complex non-disease traits and that scaling (Evo2) does not yet close the gap. The genuine tension is between the GPN paper's unqualified "powerful/state-of-the-art" framing (in *Arabidopsis*) and the more sober human-genome reality that both the GPN-MSA and benchmarking papers acknowledge.

**Insufficiency note.** The remaining context items are not about DNA-LM variant-effect benchmarking: the ESM3 ("Simulating 500 million years of evolution") and Shannon entropy papers are off-topic for this question, and PromoterAI is a supervised functional-genomics model rather than a DNA LM, so it does not bear directly on whether DNA *language* models predict variant effects well.
